We are delighted to share the publication from the STRATEGE2, a 2‑year, prospective, real‑world study, which aim to describe the therapeutic approach to methotrexate (MTX) use at the initiation of the first biologic or targeted synthetic disease-modifying antirheumatic drug (b/tsDMARD) in the treatment of rheumatoid arthritis (RA), tracking treatment strategies and disease evolution, and identifying factors driving therapeutic choices.

RCTs is proud to have supported the study from end to end, including protocol writing, eCRF development, data management, monitoring, statistical analysis, and study report preparation.

The article is available in open access: https://link.springer.com/article/10.1007/s40744-025-00806-1

Methotrexate Maintenance After Initiation of Biological or Targeted Synthetic DMARDs in Rheumatoid Arthritis: Results from the 2-Year Longitudinal Prospective Non-interventional STRATEGE2 Study

Discover our publications in rhumatology: Rheumatology – RCTs